BioCardia Reports First Quarter 2024 Business Highlights and Financial Results
14 mai 2024 16h02 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort
25 avr. 2024 09h00 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study
12 mars 2024 07h00 HE
|
BioCardia, Inc.
Centers for Medicare & Medicaid Services (CMS) approves reimbursement coverage of the confirmatory Phase III clinical trial of CardiAMP heart failure study
BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure
14 nov. 2023 07h15 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
BioCardia Announces Clarification and Next Steps on its Autologous CardiAMP Cell Therapy Programs
06 sept. 2023 07h15 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
BioCardia Announces DSMB Recommendation to Pause New Enrollment in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial While Additional Blinded Data is Collected
24 juil. 2023 07h00 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease,...
BioCardia Announces Helix™ Biotherapeutic Delivery Patent Issuance in Japan
08 juin 2023 07h00 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...